全文获取类型
收费全文 | 1441篇 |
免费 | 125篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 72篇 |
妇产科学 | 15篇 |
基础医学 | 155篇 |
口腔科学 | 42篇 |
临床医学 | 264篇 |
内科学 | 317篇 |
皮肤病学 | 23篇 |
神经病学 | 87篇 |
特种医学 | 256篇 |
外科学 | 104篇 |
综合类 | 26篇 |
预防医学 | 77篇 |
眼科学 | 15篇 |
药学 | 60篇 |
中国医学 | 6篇 |
肿瘤学 | 46篇 |
出版年
2023年 | 14篇 |
2022年 | 14篇 |
2021年 | 32篇 |
2020年 | 18篇 |
2019年 | 26篇 |
2018年 | 31篇 |
2017年 | 21篇 |
2016年 | 30篇 |
2015年 | 31篇 |
2014年 | 44篇 |
2013年 | 47篇 |
2012年 | 43篇 |
2011年 | 47篇 |
2010年 | 57篇 |
2009年 | 67篇 |
2008年 | 51篇 |
2007年 | 30篇 |
2006年 | 53篇 |
2005年 | 24篇 |
2004年 | 30篇 |
2003年 | 34篇 |
2002年 | 35篇 |
2001年 | 33篇 |
2000年 | 22篇 |
1999年 | 25篇 |
1998年 | 51篇 |
1997年 | 60篇 |
1996年 | 68篇 |
1995年 | 53篇 |
1994年 | 49篇 |
1993年 | 49篇 |
1992年 | 22篇 |
1991年 | 17篇 |
1990年 | 27篇 |
1989年 | 40篇 |
1988年 | 33篇 |
1987年 | 33篇 |
1986年 | 40篇 |
1985年 | 26篇 |
1984年 | 20篇 |
1983年 | 11篇 |
1982年 | 24篇 |
1981年 | 16篇 |
1980年 | 9篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1977年 | 15篇 |
1976年 | 12篇 |
1975年 | 14篇 |
1973年 | 4篇 |
排序方式: 共有1573条查询结果,搜索用时 31 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Victor M. Cardenas 《American journal of public health》2002,92(11):1706-1707
3.
Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients 总被引:5,自引:0,他引:5
H T Robertson N R Haley M Guthrie D Cardenas J W Eschbach J W Adamson 《American journal of kidney diseases》1990,15(4):325-332
The objective of this study was to quantitate the improvement in exercise capacity produced in anemic chronic hemodialysis (HD) patients after correction of their anemia with recombinant human erythropoietin (rHuEPO). The maximal exercise capacity and quadriceps strength of 19 anemic HD patients was tested before and after correction of the anemia with rHuEPO. A progressive work exercise protocol (PWET) on a cycle ergometer was used to compare measurements of maximal oxygen uptake (VO2max), maximal heart rate, and subjective assessment of fatigue during the test. Measurements of quadriceps strength were performed before the cycle ergometer studies. At baseline, all patients had reduced VO2max (15.3 +/- 5.4 mL/kg/min) and maximal exercise heart rates (138.5 +/- 23.9 beats/min). rHuEPO increased the mean hematocrit from 21.2% to 35%, and this was associated with a 17% increase (P less than 0.0005) in the VO2max. At any specified work load, rHuEPO treatment decreased heart rate, minute ventilation, and the subjective perception of fatigue. Both isometric and isokinetic measurements of quadriceps strength were improved following administration of rHuEPO. The maximal exercise heart rate was decreased in comparison to the baseline measurements (P less than 0.04), suggesting that in contrast to normal subjects, HD patients stop exercise before oxygen transport limitations are reached. In this unselected group of chronic HD patients, rHuEPO produced clinically significant improvements in both aerobic exercise capacity and isometric and isokinetic quadriceps strength. The improvement in aerobic capacity was substantially less than would have been expected from the correction of a comparable degree of anemia in non-HD patients. None of the 19 treated patients attained the exercise performance level predicted for a sedentary normal subject. 相似文献
4.
5.
6.
7.
J. P. Dedet R. Melogno F. Cardenas L. Valda C. David V. Fernandez M. E. Torrez L. Dimier-David P. Lyevre M. E. Villareal 《Bulletin of the World Health Organization》1995,73(3):339-345
Mucocutaneous leishmaniasis (MCL) is endemic in the tropical Amazonian lowlands of Bolivia, an area that regularly receives influxes of migratory populations. In these new agricultural development areas, a campaign to diagnose and treat the disease was carried out between 1989 and 1992, in order to provide direct access to MCL treatment in the endemic areas at a standard equivalent to that offered in the urban centres in Bolivia. The campaign led to the creation of decentralized local centres for diagnosis and treatment of the disease. A campaign to inform the population about leishmaniasis was also undertaken and courses were run to educate medical and paramedical personnel. As a result of the campaign, 3285 cases of leishmaniasis were diagnosed, including 2152 cutaneous and 326 mucosal forms. Also, a total of 1888 cases were treated, 1677 of which cutaneous and 211, mucosal. 相似文献
8.
9.
10.
Gingival augmentation for osseointegrated implant prostheses 总被引:1,自引:0,他引:1
S M Parel T J Balshi D Y Sullivan E R Cardenas 《The Journal of prosthetic dentistry》1986,56(2):208-211
A method of solving some problems inherent with osseointegrated implant prosthesis has been presented. A removable flange can reestablish lip support or block escape of unwanted air while allowing the access necessary for competent hygiene procedures. Overdentures may be indicated to provide the prosthetic gingival surface necessary for adequate food control or speech. 相似文献